"Do they say how much eGFR went up by?  My guess estimate for RVX208 is about 5% increase in 12 months...but could be higher.  Based on what you are saying here, that should qualify for breakthrough designation."

Just be careful to make sure you are comparing apples to apples when comparing eGFR changes. Lots of different types of kidney disease are in the fruit basket. Reata has completed or ongoing trials in autosomal dominant polycystic kidney disease, Alport syndrome, IgA nephropathy, focal segmental glomerulosclerosis, type 1 diabetes CKD and type 2 diabetes CKD. It seems that they may have run into some adverse events in the type 2 diabetes CKD program. By the way, don't ask me to explain these different kidney diseases..... I just copied and pasted the names! 

BearDownAZ